(Reuters) -Pfizer Inc and companion BioNTech have accomplished the submitting with the U.S. medicine regulator in search of authorization for his or her COVID-19 vaccine in kids below 5 years of age.

The submitting with the U.S. Meals and Drug Administration (FDA), accomplished on Wednesday, included information displaying three lower-dose pictures of the vaccine generated a powerful immune response in kids as younger as 6 months of age.

No COVID-19 shot is but accepted for kids in that age group in most elements of the world. It stays unclear what number of mother and father will get their younger ones vaccinated as demand has been low in youngsters aged 5 to 11.

Pfizer (NYSE:) and BioNTech on Could 23 mentioned their trial confirmed a 3 microgram model of the vaccine generated the same immune response in below 5-year-olds as two doses of 30 micrograms every in 16 to 25-year-olds in an earlier trial.

Rival Moderna (NASDAQ:) in March launched trial information that confirmed a two-dose formulation of its vaccine was protected and generated the same immune response in younger kids as in adults.

The FDA’s impartial advisers will focus on the 2 functions in a gathering set for June 15.